

Synthesis and Biological Evaluation of Cruentaren A Analogues

Viktor V. Vintonyak,^[a] Marcellino Calà,^[a] Frank Lay,^[a] Brigitte Kunze,^[b] Florenz Sasse,^[c] and Martin E. Maier*^[a]

Abstract: The complex macrolide cruentaren A is a highly selective and potent inhibitor of F-ATPase (F-type adenosine triphosphatase). As it shows some resemblance to benzolactone enamides like apicularen A, it was of interest to perform some structure–activity studies to delineate the key functional groups that are responsible for the activity. Building upon our previously developed route to cruentaren A,


which is based on a ring-closing alkyne metathesis reaction (RCAM), several cruentaren analogues were prepared. Replacement of the 3-hydroxy hexanoic part with acids that lack the hydroxy

Keywords: cruentaren • cyclization reactions • enzyme inhibitors • lactones • metathesis • Natural products

group function resulted in a significant drop in cytotoxicity and F-ATPase inhibition. Furthermore, two enamide analogues **23** and **50** were synthesized. However, these compounds were only cytotoxic in the micromolar range. Under the conditions for cleavage of the C3 aromatic methyl ether, the enamide function was transformed to the corresponding oxazinanone, resulting in analogues **25** and **52**.

Introduction

Recently, Höfle and co-workers described the structure of the macrolide cruentaren A (**1**).^[1,2] This unique natural product was isolated from the myxobacterium *Byssovorax cruenta* (Scheme 1). In a cellular assay with the L929 cell line, cruentaren A showed powerful cytotoxicity with an IC₅₀ value of 1.2 ng mL^{−1}. Further studies revealed that on a molecular level, cruentaren A inhibits mitochondrial F-ATPase (F-ATPase = F-type adenosine triphosphatase).^[3,4] These membrane-bound proteins are crucial for a living cell as they use a proton gradient to power the synthesis of ATP. Key structural features of cruentaren A include a 12-mem-



Scheme 1. Structure of cruentaren A.

bered macrolactone with a Z double bond. The side chain extending from C15 contains a stereotetrad and an (Z)-allylamide terminus. Interestingly, cruentaren A does not show much similarity to other polyketide inhibitors of F-ATPase, such as apoptolidin or oligomycin.^[5]


Other natural products with an allylamide include leucascandrolide^[6,7] (**2**) (Scheme 2), neopeltolide,^[8] callipeltoside^[9,10] and ajudazol A (**3**).^[11] Except for ajudazol A, which was reported to be an inhibitor of mitochondrial electron transport, the mode of action of the other mentioned compounds still remains unclear. Furthermore, a similarity of cruentaren A to the benzolactone enamides,^[12] like apicularen A (**4**) was noted.^[2] However, cruentaren A does not inhibit V-ATPase (V-type ATPase),^[3,13] the target of the ben-

[a] Dipl.-Chem. V. V. Vintonyak, Dipl.-Chem. M. Calà, Dipl.-Chem. F. Lay, Prof. Dr. M. E. Maier
Institut für Organische Chemie, Universität Tübingen
Auf der Morgenstelle 18, 72076 Tübingen (Germany)
E-mail: martin.e.maier@uni-tuebingen.de

[b] Dr. B. Kunze
Arbeitsgruppe Mikrobielle Kommunikation
Helmholtz-Zentrum für Infektionsforschung
Inhoffenstrasse 7, 38124 Braunschweig (Germany)

[c] Dr. F. Sasse
Abteilung Chemische Biologie
Helmholtz-Zentrum für Infektionsforschung
Inhoffenstrasse 7, 38124 Braunschweig (Germany)

Supporting information for this article is available on the WWW under <http://www.chemurj.org/> or from the author.




Scheme 2. Structures of some natural products that resemble cruentaren A.

zolacone enamides. Therefore, it would be of interest to identify some key structural elements that are decisive for the biological activity of cruentaren A.


In previous papers, we outlined an efficient synthetic strategy towards cruentaren A.^[14,15] The macrolactone ring was formed through a ring-closing alkyne metathesis reaction^[16,17] on the ester **5** by using the Schrock catalyst **6** (Scheme 3). To prevent an unwanted translactonization to the six-membered lactone, extension of the side chain was done on the cyclic alkyne **7**. Thus, the aldehyde derived from **7** was converted to the alkyne **8** through the Bestmann–Ohira reaction. Extension of the terminal alkyne with formaldehyde allowed for the formation of the key propargyl amine **9** through the Mitsunobu reaction. Condensation of the amine **9** with the protected 3-hydroxy acid **10** led to the amide **11**. Finally, cleavage of the C3 OMe ether, the silicon protecting groups and Lindlar hydrogenation completed the total synthesis of cruentaren A.^[15] Recently, another ring-closing alkyne metathesis (RCAM)-based synthesis of cruentaren A was achieved by Fürstner et al.^[18]

With regard to the design of analogues, we wanted to use the available stereotetrad building blocks^[14] and stick to the proven RCAM reaction. We intended to answer the following questions: How important is the carboxylic acid part of the amide? How important is the free OH at C3? Can we make enamides instead of (*Z*)-allylamides? Although quite speculative, it could be that the allylamide isomerizes to an enamide that then might form a highly electrophilic acyliminium ion upon protonation (Scheme 4).^[19]

Herein, we describe the synthesis together with the biological evaluation of several cruentaren A analogues.



Scheme 3. Key steps in the synthesis of cruentaren A; DMB = 3,4-dimethoxybenzyl, TBS = *tert*-butyldimethylsilyl, TIPS = triisopropylsilyl.




Scheme 4. Possible isomerization of the allylamide to an enamide.

Results and Discussion

Synthesis: We began with the preparation of the 3-*O*-methyl ether of cruentaren. As outlined in Scheme 3, the synthesis of **1** passed through the diyne **11**. Omitting the cleavage of the C3 methyl ether and instead treating the lactone **11** with the HF·pyridine complex led to the triol **12** (Scheme 5). A final Lindlar reduction delivered 3-*O*-methyl cruentaren **13**.


Another key intermediate of the total synthesis, the propargyl amine **9**, presented itself for derivatization reactions. Accordingly, the amine **9** was condensed with the acids **14a–d** by using 2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) in the presence of 1-hydroxy-1*H*-benzotriazole (HOBt) and Hünig's base in *N,N*-dimethylformamide (DMF; Scheme 6). These acylation reactions proceeded in quite good yields (Table 1). For these derivatives, we chose to generate the original aromatic part



Scheme 5. Synthesis of 3-OMe cruentaren **13** from the amide **11**. Py=pyridine.

with the 3-OH group. Selective ether cleavage on the lactones **15a–d** by using boron trichloride furnished the corresponding 3-hydroxy compounds **16a–d**, again in excellent yields. The Lindlar reduction of the diynes **17b** and **17c** proceeded as expected to give the analogues **18b** and **18c**. From the reduction of diyne **17a**, the analogue **18a** was obtained, but we also isolated the dihydro compound **18e**, resulting from hydrogenation of the cinnamoyl double bond. In the case of the hept-2-en-4-ynamide **17d**, only the product **18f** resulting from complete hydrogenation was observed. The internal *Z* double bond survived as in the other amide analogues.

As a further branching point for the synthesis of the analogues, we identified the lactone **8** with a propynyl terminus. We thought that the derived vinyl iodide might be useful for the synthesis of enamide derivatives. With this in mind, diyne **8** was subjected to hydrozirconation with the Schwartz reagent followed by addition of iodine to the intermediate vinylmetal species (Scheme 7).^[20] Thereafter, a copper-catalysed cross-coupling reaction of vinyl iodide **19** with the amide **20** under Buchwald conditions^[21–26] was performed, resulting in enamide **21** in high yield. Owing to the expected sensitivity of the enamide to harsh acidic conditions, the demethylation step was omitted. Nevertheless, the enamide survived the conditions (HF-pyridine complex) for global deprotection of the silyl ethers. A Lindlar reduction on diyne **22** completed the synthesis of enamide analogue **23**.




Scheme 6. Preparation of various amide analogues of cruentaren A. HBTU = *O*-(1*H*-benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphates.

Table 1. Yields for the various steps for the synthesis of amide analogues **18** of cruentaren A.

Acid used	Transformation			Lindlar's catalyst [%]
	acylation [%]	BCl ₃ [%]	HF·py [%]	
14a	87	92	95	74 ^[a]
14b	88	86	93	93
14c	91	83	85	87
14d	85	89	92	73 ^[b]

[a] By-product dihydro derivative **18e**. [b] Only the saturated heptanoyl derivative **18f** was formed under the Lindlar conditions.


If however, the enamide **21** was treated with boron trichloride to cleave the C3 O-methyl ether, followed by global silyl removal with HF-pyridine complex, a compound (**24**), which lacked the enamide signals in the ^1H NMR spectrum was isolated (Scheme 8). According to LC-MS analysis, the mass was the same as expected for the enamide. The



Scheme 7. Preparation of the enamide analogue **23** of cruentaren A.

signal at $\delta=5.02$ ppm in the ^1H NMR spectrum pointed to the presence of the 1,3-oxazinan-4-one. The formation of this heterocyclic ring system can easily be explained by the corresponding acyliminium ion. Although we were not able to unambiguously assign the stereochemistry at the aminal carbon, we assume a 2,6-*cis*-configuration (oxazinone-4-numbering). Force-field calculations using Chem3D on 2,5,6-trimethyl-1,3-oxazinan-4-one showed the *cis*-2,6-diastereomer to be 5.65 kJ mol $^{-1}$ more stable than the corresponding 2,6-*trans* isomer. Lindlar reduction of the triple bond led to the oxazinan-4-one analogue **25**. It can be assumed that oxazinanone formation occurs upon treatment of the enamide **21** with BCl_3 as the HF-pyridine complex does not seem to affect the enamide as could be seen with the deprotection of **21** to enamide **22**.


To further probe the potential biological relevance of a cruentaren A enamide, the homologated enamide derivative of analogue **25** was targeted. In this case, we could have used macrolactone **8**, with a propyne terminus, as the starting material, but instead we began with the stereotetrad-containing building block^[14] **26** (Scheme 9). This compound,



Scheme 8. Formation of the oxazinanone system during methyl ether cleavage on enamide **21** with BCl_3 resulting in analogue **25**.

which originated from a Marshall–Tamaru reaction,^[14,27] was extended to the propargyl alcohol **27**. A hydrogenation reaction provided the propanol derivative **28**. Protection of the hydroxyl group function with dimethoxybenzyl imidate^[28] to give **29** was followed by cleavage of the isopropylidene group by using aqueous copper(II) chloride^[29] to provide diol **30**. The 1,2-diol was converted to the epoxide **32** by using the arylsulfonyl derivative **31**.^[30] The stage was now set for epoxide opening with lithium trimethylsilylacetylide in the presence of $\text{BF}_3\cdot\text{OEt}_2$.^[31,32] Silylation of **33** and removal of the acetylenic silyl group from **34** furnished alkyne **35**. In preparation for the RCAM reaction, the terminal alkyne **35** was converted to the inner alkyne **36** by using *n*BuLi followed by MeI. The subsequent treatment of bis-silyl ether **36** with tetrabutylammonium fluoride (TBAF) delivered diol **37**. A possible shortcut from epoxide **32** to the alkyne **36** was attempted by direct opening of the epoxides with propynyllithium. Unfortunately, the major product in this reaction by using propynyllithium prepared *in situ* from 1-bromopropene^[33] turned out to be the corresponding bromohydrin.

As we had outlined in the synthesis of the core structure, esterification of benzoic acid **38** with building block **37** was best performed with the diol itself. After conversion of the acid to the carbonylimidazolid **39**, esterification with the sodium alcoholate of **37** went smoothly and in a regioselective manner (Scheme 10).^[34] Silylation of the free hydroxy group function of **40** gave rise to the ester **41**, the substrate




Scheme 9. Synthesis of the alkynediol **37** from terminal alkyne **26**. CDI = *N,N*-carbonyl diimidazole, PPTS = *p*-toluenesulfonate.

for the alkyne metathesis reaction. Based on the diol **37**, the yield for the ester **41** amounted to 67 %. The RCAM^[16,35] reaction of **41** with the Schrock catalyst^[36] **6** proceeded in excellent chemical yield, furnishing lactone **42**. To set up an (*E*)-vinyl iodide at the side-chain terminus, the DMB protecting group was removed under oxidative conditions.^[37] The resulting primary alcohol **43** was oxidized to the aldehyde **44**. Extension of the aldehyde **44** to the alkyne could be accomplished with the Bestmann–Ohira reagent^[38] **45** in the presence of K₂CO₃. Finally, hydrozirconation and iodination provided the vinyl iodide **47**.

As outlined before, a cross-coupling reaction of vinyl iodide **47** with the amide **20** was used to set up the enamide functionality (Scheme 11). Global silicon ether cleavage on **48** and Lindlar reduction of the triple bond furnished analogue **50**.

If the enamide **48** was treated with BCl₃, cleavage of the C3 OMe ether was accompanied by the formation of the oxazinan-4-one **51** (Scheme 12). The analogue **52** was obtained through silyl group removal and the Lindlar reduction. Characteristic peaks for the oxazinanone part of **52** are as follows: δ = 4.71 (2-H; 22-H), 6.40 ppm (N-H); ¹³C NMR: δ = 83.8 (C2; C22), 174.6 (C4; C23), 38.8 (C5; C24), 72.9 (C6; C25) ppm.

The formation of 1,3-oxazinan-4-ones from enamides containing a β-hydroxy acid seems to be unprecedented. Similar



Scheme 10. Synthesis of the macrolactone **47** featuring a 4-iodobutenyl side chain. DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

oxazinanones have been generated by condensation of aromatic aldehydes with alicyclic 2-hydroxy-1-carboxamides.^[39] For such oxazinanone derivatives, a 2,6-*cis*-configuration was observed. The synthesis for 5-phenylthio-1,3-oxazinan-4-ones is based on the hetero Diels–Alder reaction between an azadiene and an aldehyde.^[40] Other 1,3-oxazinanones are known as well.^[41,42,43]


Biological testing: The described analogues as well as the diyne **53** were tested for cytotoxicity against the L929 cell line and the inhibitory efficacy on F-ATPase in mitochondrial preparations of bovine heart. The obtained IC₅₀ values in the cell-culture assay as well as the percentage of F-ATPase inhibition of the compounds at a concentration of 0.1 and 1.0 μM, respectively, are listed in Table 2. The analogues are ordered according to increasing IC₅₀ values against the L929 cell line.

Table 2. Biological activity of cruentaren A (cru) and the analogues.

Entry	Compound	IC ₅₀ [μg mL ⁻¹]	IC ₅₀ [μM]	Inhibition of F-ATPase activity [%] ^[a]		Description
				1 μM	0.1 μM	
1	1	0.00042 ± 0.00005	0.00071 ± 0.00008	94	78	cru (synthetic) ^[b]
2	13	0.017 ± 0.004	0.028 ± 0.007	80	42	3-OMe-cru
3	52	0.085 ± 0.02	0.14 ± 0.03	34	2	7C-oxazinanone-cru
4	18c	0.3 ± 0.01	0.56 ± 0.02	44	30	isobutanoyl-cru
5	18e	2.4 ± 0.1	4.0 ± 0.2	47	32	dihydro-cinnamoyl-cru
6	18b	2.5 ± 0.1	4.5 ± 0.2	47	27	hexanoyl-cru
7	18f	2.9 ± 0.3	5.0 ± 0.5	67	48	heptanoyl-cru
8	50	3.0 ± 0.4	5.0 ± 0.7	47	8	7C-enamide-cru
9	23	3.0 ± 1.1	5.1 ± 1.9	51	15	6C-enamide-cru
10	18a	6.1 ± 0.7	10.3 ± 1.2	40	30	cinnamoyl-cru
11	53	6.5 ± 0.4	11.1 ± 0.7	21	10	diyne-cru
12	25	7.5 ± 0.9	13.0 ± 1.6	18	12	6C-oxazinanone-cru


[a] The inhibition values are the mean values of at least two independent assays. The deviations did not exceed a range of ±10% inhibition. [b] The natural cruentaren A displayed a slightly lower activity (IC₅₀ = (0.002 ± 0.0019) μM, F-ATPase inhibition = 93% at 1 μM). This might be attributed to different purity values. The value for the synthetic product does lie within the deviation of the natural material.

active with a side chain of seven carbons can be considered as highly cytotoxic, but it showed only low inhibitory efficacy in the F-ATPase assay (seven-carbon, entry 3). Then there are compounds of intermediate cytotoxicity and F-ATPase inhibition, namely the cruentaren derivatives with a modified carboxylic part in the side chain (**18e**, **18b**, **18f**; Table 2, entries 5–7). In particular **18c** and **18b** make clear that the OH group of the carboxylic acid part is extremely important. Finally, there are compounds that are essentially nontoxic, starting



Scheme 11. Synthesis of the enamide analogue **50**.

As can be seen in Table 2, there are some highly effective compounds. In most cases, cytotoxicity and inhibitory activity against F-ATPase in vitro run parallel. However, there are some exceptions in this regard. For example, **18c** and the three analogues **18e**, **18b** and **18f** differ in their cellular activity by a factor of almost 10, but display similar effects on the F-ATPase. This might be explained by differences in cellular uptake. The highest effective compound is cruentaren A itself (Table 2, entry 1), followed by 3-OMe cruentaren (**13**) (Table 2, entry 2). Furthermore, the oxazinanone deriv-



Scheme 12. Synthesis of the oxazinan-4-one analogue **52** and the diyne cruentaren **53**.

with compound **18a**. Surprisingly, both enamides show neither a high cytotoxicity, nor significant inhibition of F-ATPase. One hypothesis in the design of the enamide analogues was that with a structural resemblance to typical V-

ATPase inhibitors like apicularen A or salicylilalamide A, these analogues would show corresponding activity. As it could be assumed that a V-ATPase inhibitor would be highly cytotoxic, this shows that the enamide side is not sufficient to convert the F-ATPase inhibitor cruentaren A into a V-ATPase inhibitor. The most puzzling observation is the relatively high cytotoxicity of the oxazinanone **52**, which shows only low inhibition of F-ATPase. We also checked for inhibitory effects on V-ATPase with PtK₂ potoroo cells. However, when we investigated treated cells by fluorescent techniques, we did not observe the characteristic changes in the endoplasmatic reticulum that are typical for V-ATPase inhibitors. One explanation for the cytotoxicity of **52** could be that the heterocyclic ring is opened to an electrophilic acyliminium ion when taken up by the cells. The lack of activity for diene cruentaren **53** can be attributed to conformational effects.

Conclusion

By using the RCAM strategy that led to the total synthesis of cruentaren A (**1**), a range of cruentaren analogues were prepared. Replacing the 3-hydroxy-hexanoic acid gave analogues **18a**, **18b**, **18c**, **18e**, **18f**, however, with the exception of the truncated isobutanoyl analogue **18c**, none of the analogues were highly active. Furthermore, the two enamide analogues **23** and **50** were prepared via cross-coupling (amination) of the corresponding vinyl iodides **19** and **47**, respectively. As the enamides did not survive the conditions (BCl₃) of the cleavage of the aromatic methyl ether, we prepared the 3-OMe derivatives. Even though this methyl ether is important (see **1** and **13**), the complete lack of activity for the two enamides **23** and **50** is somewhat surprising. Upon cleavage of the 3-OMe ether with BCl₃, the enamide function of **21** and **49** reacted with the hydroxyl group function of the carboxylic acid to give an unusual oxazinanone heterocycle. Among the two oxazinanone analogues, compound **52**, which might be a metabolite of **1**, was quite active and showed an IC₅₀ value of 140 nM. This work also constitutes a novel synthesis of 1,3-oxazinan-4-ones from enamides.

Experimental Section

General details are included in the Supporting Information. The experimental details for Scheme 5, part of Scheme 6, Scheme 8 and Scheme 9 are covered in the Supporting Information as well. The pH 7 buffer was prepared by dissolving KH₂PO₄ (85 g, 0.625 mol) and NaOH (14.5 g, 0.3625 mol) in water (1 L).

Cinnamic acid amide (15a): (*E*)-cinnamic acid (6.4 mg, 0.043 mmol, 1.6 equiv), HBTU (20.5 mg, 0.054 mmol, 2 equiv), HOBt (7.3 mg, 0.054 mmol, 2 equiv), and N,N-diisopropylethylamine (48 µL, 0.27 mmol, 10 equiv) were added to a solution of amine^[15] **9** (20 mg, 0.027 mmol, 1 equiv) in dry DMF (2 mL). After the mixture was stirred at room temperature for 4 h, H₂O (5 mL) was added and the obtained emulsion was extracted with Et₂O (3 × 15 mL). The combined organic layers were washed with saturated NaHCO₃ solution (10 mL), dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by flash chromatography (petroleum ether/EtOAc, 10:1→4:1) to give 20.5 mg (87%) of amide **15a** as a colourless amorphous solid. TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.39; [α]_D²⁰ = −13.1 (*c* = 1.4, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.04 (s, 3H, Si(CH₃)₂), 0.06 (s, 3H, Si(CH₃)₂), 0.87–1.02 (m, 39H, 16-CH₃, 18-CH₃, 10-CH₃, Si(C(CH₃)₃), Si(CH(CH₃)₂)₃), 1.72–1.83 (m, 1H, 16-H), 1.91–2.11 (m, 3H, 19-H, 18-H), 2.12–2.20 (m, 1H, 11-H), 2.22–2.30 (m, 1H, 10-H), 2.33–2.55 (m, 4H, 8-H, 14-H, 11-H), 3.60–3.65 (m, 1H, 17-H), 3.73 (s, 3H, OCH₃), 3.75–3.83 (m, 4H, OCH₃, 8-H), 4.00–4.18 (m, 3H, 9-H, 22-H), 5.47–5.59 (m, 1H, 15-H), 6.02 (br s, 1H, NH), 6.31 (d, *J* = 2.0 Hz, 1H, 6-H), 6.40–6.46 (m, 2H, 4-H, 25-H), 7.29–7.34 (m, 3H, *o*-, *p*-CH of Ph), 7.41–7.47 (m, 2H, *m*-CH of Ph), 7.62 ppm (d, *J* = 15.7 Hz, 1H, 24-H); ¹³C NMR (100 MHz, CDCl₃): δ = −3.9 (Si(CH₃)₂), 11.4 (16-CH₃), 13.0 (CH(CH₃)₂), 17.2 (10-CH₃), 17.9 (CH(CH₃)₂), 18.1 (CH(CH₃)₂), 18.4 (18-CH₃), 21.7 (C19), 23.1 (C14), 23.7 (C11), 26.1 (Si(C(CH₃)₃)), 30.0 (C22), 37.2 (C18), 37.3 (C16), 38.6 (C8), 40.3 (C10), 55.2 (OCH₃), 55.7 (OCH₃), 75.0 (C17), 76.6 (C9), 77.2 (C15), 79.6 (C=C), 81.7 (C=C), 83.2 (C=C), 96.6 (C4), 108.2 (C6), 118.0 (C2), 120.2 (C24), 127.8 (C4'), 128.7 (C3'), 129.6 (C2'), 134.8 (C1'), 139.4 (C7), 141.2 (C25), 157.4 (C5), 160.4 (C3), 165.4 (C1), 167.6 ppm (C23); HRMS (ESI): [*M*+Na]⁺ calcd for C₅₁H₇₇NNaO₇Si₂ 894.51308, found 894.51309.

2-Hydroxy-4-methoxybenzoate (16a): A solution of amide **15a** (18 mg, 0.02 mmol) in CH₂Cl₂ (3 mL) was treated with BCl₃ (80 µL, 1.0 M in CH₂Cl₂, 0.08 mmol, 4 equiv) at −80 °C. The reaction was stirred for 2 h at −80 °C before a saturated solution of NaOAc (3 mL) was added. After separation of the layers, the aqueous phase was extracted twice with CH₂Cl₂. The combined organic layers were washed with H₂O followed by saturated NaCl solution, dried over MgSO₄, filtered and concentrated in vacuo. Flash chromatography (petroleum ether/EtOAc, 4:1) afforded phenol **16a** (15.8 mg, 92%) as a slightly yellow oil. TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.4; [α]_D²⁰ = +17.0 (*c* = 0.7, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.05–0.08 (m, 6H, Si(CH₃)₂), 0.85–1.05 (m, 39H, 16-CH₃, 18-CH₃, 10-CH₃, Si(C(CH₃)₃), Si(CH(CH₃)₂)₃), 1.67–1.91 (m, 2H, 16-H, 19-H), 1.94–2.20 (m, 4H, 19-H, 18-H, 11-H), 2.23–2.35 (m, 2H, 10-H, 14-H), 2.44–2.52 (m, 1H, 8-H), 2.55–2.67 (m, 1H, 14-H), 2.85–2.97 (m, 1H, 8-H), 3.56–3.62 (m, 1H, 17-H), 3.77 (s, 3H, OCH₃), 4.10–4.15 (m, 2H, 22-H), 4.17–4.25 (m, 1H, 9-H), 5.19–5.28 (m, 1H, 15-H), 5.81 (br s, 1H, NH), 6.33–6.42 (m, 3H, 6-H, 4-H, 25-H), 7.32–7.39 (m, 3H, *o*-, *p*-CH of Ph), 7.47–7.53 (m, 2H, *m*-CH of Ph), 7.64 (d, *J* = 15.7 Hz, 1H, 24-H), 11.22 ppm (br s, 1H, 3-OH); ¹³C NMR (100 MHz, CDCl₃): δ = −4.0 (Si(CH₃)₂), 11.1 (16-CH₃), 13.0 (CH(CH₃)₂), 16.6 (10-CH₃), 18.2 (CH(CH₃)₂), 18.2 (CH(CH₃)₂), 18.4 (18-CH₃), 22.1 (C19), 22.7 (C14), 26.0 (Si(C(CH₃)₃)), 30.0 (C22), 36.7 (C18), 37.4 (C16), 55.2 (OCH₃), 74.6 (C17), 75.6 (C9), 76.9 (C=C), 77.2 (C15), 82.7 (C=C), 83.2 (C=C), 98.9 (C4), 104.2 (C6), 119.7 (C2), 120.0 (C24), 127.8 (C4'), 128.8 (C3'), 129.8 (C2'), 134.7 (C1'), 141.6 (C7), 143.3 (C25), 163.4 (C3), 164.6 (C5), 165.3 (C1), 171.1 ppm (C23); HRMS (ESI): [*M*+Na]⁺ calcd for C₅₀H₇₅NO₇Si₂Na 880.49743, found 880.49810.

Deprotected macrolactone (17a): HF-pyridine complex (70% HF, 0.3 mL) was added dropwise to a stirred solution of the phenol **16a** (14 mg, 0.016 mmol) in THF (0.4 mL, in a plastic test tube) at −80 °C. The reaction mixture was allowed to warm to −5 °C. After 2 h, the mixture was partitioned between an ice-cooled mixture of EtOAc (20 mL) and a saturated aqueous NaHCO₃ solution (20 mL). The organic layer was separated and the H₂O layer extracted with EtOAc (2 × 20 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by flash chromatography (CH₂Cl₂/MeOH, 95:5→9:1) to give 9.0 mg (95%) of triol **17a**. TLC (CH₂Cl₂/MeOH, 9:1): *R*_f = 0.56; [α]_D²⁰ = +11.7 (*c* = 0.8, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.91–0.96 (m, 6H, 16-CH₃, 18-CH₃), 1.02 (d, *J* = 6.8 Hz, 3H, 10-CH₃), 1.74–1.85 (m, 2H, 16-H, 18-H), 2.00–2.10 (m, 2H, 19-H, 18-H), 2.15–2.27 (m, 4H, 19-H, 11-H, OH), 2.28–2.37 (m, 2H, 11-H, 8-H), 2.38–2.46 (m, 1H), 2.57–2.65 (m, 1H, 14-H), 2.77–2.85 (m, 1H, 14-H), 2.88–2.98 (m, 1H, 10-H), 3.63–3.69 (m, 1H, 17-H), 3.72–3.76 (m, 1H, 8-H), 3.91–3.99 (m, 1H, 9-H), 4.11–4.16 (m, 2H, 22-H), 5.32–5.39 (m, 1H, 15-H), 5.97 (br s, 1H, NH), 6.34–6.43 (m, 3H, 6-H, 4-H, 25-H), 7.33–7.40 (m, 3H, *o*-, *p*-CH of Ph), 7.46–7.52 (m, 2H, *m*-CH of Ph), 7.63 (d, *J* = 15.7 Hz, 1H, 24-H), 11.00 ppm (br s, 1H, 3-OH); ¹³C NMR (100 MHz, CDCl₃): δ = 8.5 (16-CH₃), 14.1 (24-CH₃), 16.2 (18-CH₃), 16.5 (10-CH₃), 21.1 (C19), 22.5 (C14), 23.0 (C11), 29.9 (C22), 35.7 (C26), 36.7

(C18), 37.3 (C16), 38.4 (C8), 55.4 (OCH₃), 73.8 (C17), 75.3 (C9), 77.2 (C15), 77.6 (C=C), 79.3 (C=C), 81.8 (C=C), 83.3 (C=C), 99.5 (C4), 106.5 (C2), 111.5 (C6), 120.0 (C24), 127.8 (C4'), 128.8 (C3'), 129.8 (C2'), 134.7 (C1'), 141.7 (C7), 143.2 (C25), 163.7 (C5), 164.5 (C3), 165.5 (C1), 170.7 ppm (C23); HRMS (ESI): [M+Na]⁺ calcd for C₃₅H₄₁NaNO₇ 610.27752, found 610.27802.

Cinnamoyl cruentaren (18a) and dihydrocinnamoyl cruentaren (18e): Lindlar's catalyst (5 wt % Pd on CaCO₃, poisoned with lead, 4.2 mg, 100 wt %) was added to a stirred solution of diyne **17a** (4.2 mg, 0.007 mmol) in EtOAc (2 mL) containing quinoline (1.5 mg, 0.01 mmol). The reaction was placed under H₂ atmosphere and stirred for 1 h. The mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. Flash chromatography of the residue (CH₂Cl₂/MeOH, 95:5→9:1) afforded cinnamide **18a** (3.1 mg, 74 %) and phenylpropionamide **18e** (1.0 mg, 24 %).

18a: TLC (CH₂Cl₂/MeOH, 9:1): R_f=0.64; [α]_D²⁰=+8.3 (c=0.3, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ=0.80 (d, J=6.8 Hz, 3H, 18-CH₃), 0.92 (d, J=7.1 Hz, 3H, 16-CH₃), 0.97 (d, J=6.8 Hz, 3H, 10-CH₃), 1.70–1.79 (m, 2H, 18-H, OH), 1.93–2.06 (m, 3H, 10-H, 11-H, 16-H), 2.16–2.26 (m, 2H, 14-H, 19-H), 2.28–2.40 (m, 3H, 11-H, 8-H, 19-H), 2.79–2.96 (m, 1H, 14-H), 3.51 (dd, J=9.4 Hz, 1.8 Hz, 1H, 17-H), 3.61–3.67 (m, 1H, 9-H), 3.72–3.74 (m, 1H, 8-H), 3.75–3.80 (m, 4H, OCH₃, OH), 3.87–3.95 (m, 1H, 22-H), 4.05–4.14 (m, 1H, 22-H), 5.27–5.35 (m, 1H, 15-H), 5.42–5.52 (m, 3H, 21-H, 12-H, 13-H), 5.53–5.63 (m, 1H, 20-H), 6.02 (br s, 1H, NH), 6.30 (d, J=2.6 Hz, 1H, 6-H), 6.35–6.41 (m, 2H, 4-H, 25-H), 7.32–7.39 (m, 3H, *o*-, *p*-CH of Ph), 7.46–7.51 (m, 2H, *m*-CH of Ph), 7.62 (d, J=15.7 Hz, 1H, 24-H), 11.50 ppm (br s, 1H, 3-OH); HRMS (ESI): [M+Na]⁺ calcd for C₃₅H₄₅NaNO₇ 614.30882, found 614.30923.

18e: TLC (CH₂Cl₂/MeOH, 9:1): R_f=0.58; [α]_D²⁰=+6.4 (c=0.1, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ=0.77 (d, J=6.8 Hz, 3H, 18-CH₃), 0.90 (d, J=7.1 Hz, 3H, 16-CH₃), 1.00 (d, J=6.6 Hz, 3H, 10-CH₃), 1.63–1.77 (m, 1H, 18-H), 1.90–2.50 (m, 12H, 10-H, 11-H, 16-H, 14-H, 19-H, 8-H, 25-H, OH), 2.78–2.90 (m, 1H, 14-H), 2.91–2.99 (m, 2H, 24-H), 3.43–3.50 (m, 1H, 17-H), 3.61–3.67 (m, 1H, 9-H), 3.72–3.82 (m, 5H, 8-H, 22-H, OCH₃), 3.85–3.97 (m, 1H, 22-H), 5.25–5.36 (m, 2H, 15-H, 21-H), 5.40–5.59 (m, 3H, 12-H, 13-H, 20-H), 5.7 (br s, 1H, NH), 6.28–6.32 (m, 1H, 6-H), 6.34–6.39 (m, 1H, 4-H), 7.15–7.22 (m, 3H, *m*-, *p*-CH of Ph), 7.24–7.31 (m, 2H, *o*-CH of Ph), 11.50 ppm (br s, 1H, 3-OH); HRMS (ESI): [M+Na]⁺ calcd for C₃₅H₄₇NO₈Na 616.32447, found 616.32467.

(E)-Vinyl iodide (19): [Cp₂Zr(H)Cl] (31 mg, 0.12 mmol) was added to a solution of alkyne^[15] **8** (44 mg, 0.06 mmol) in THF (1.5 mL) at 0 °C and the resulting mixture was stirred for 2 h at 0 °C. A solution of I₂ (0.24 mL, 0.5 M in THF, 0.12 mmol) was then added dropwise and stirring was continued for 2 h. The reaction was quenched with saturated aqueous Na₂S₂O₃ solution (5 mL). The mixture was repeatedly extracted with Et₂O. The combined organic layers were dried over MgSO₄, filtered and evaporated, and the residue was purified by flash chromatography (petroleum ether/EtOAc, 4:1) to give (E)-vinyl iodide **19** as an amorphous solid (52 mg, 92 %), which was used directly in the next step. TLC (petroleum ether/EtOAc, 4:1): R_f=0.74.

Enamide 21: A Schlenk tube was charged with CuI (10.5 mg, 0.055 mmol, 1 equiv), amide^[44] **20** (28.5 mg, 0.11 mmol, 2 equiv) and Cs₂CO₃ (46 mg, 0.14 mmol, 2.5 equiv). The tube was evacuated and backfilled with argon. N,N'-Dimethylethylenediamine (12.0 μL, 0.11 mmol, 2 equiv), vinyl iodide **19** (52 mg, 0.055 mmol) and THF (1.0 mL) were added under argon. The Schlenk tube was closed and immersed in an oil bath, which was preheated to 60 °C. The mixture was stirred for 14 h. After the resulting pale-blue suspension was allowed to reach room temperature, ethyl acetate (5 mL) was added. The reaction mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. The residue was purified by flash chromatography (petroleum ether/EtOAc, 10:1→4:1) to give enamide **21** as an amorphous solid (44 mg, 82 %). TLC (petroleum ether/EtOAc, 4:1): R_f=0.66; [α]_D²⁰=−23.5 (c=1.6, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ=0.03–0.07 (m, 6H, Si(CH₃)₂), 0.08–0.11 (m, 6H, Si(CH₃)₂), 0.84–0.98 (m, 48H, 24-CH₃, 27-H, 16-CH₃, Si(C(CH₃)₃), Si(CH(CH₃)₂)₃), 1.02–1.10 (m, 6H, 18-CH₃, 10-CH₃), 1.16–1.26 (m, 1H, 26-H), 1.31–1.50 (m, 3H, 25-H, 26-H), 1.65–1.75 (m, 2H, 18-H, 16-H), 1.76–1.84 (m, 1H, 11-H), 1.90–1.99 (m, 1H, 10-H), 2.10–2.27 (m, 2H, 19-

H), 2.35–2.54 (m, 5H, 8-H, 14-H, 23-H, 11-H), 3.45–3.49 (m, 1H, 17-H), 3.72–3.78 (m, 8H, OCH₃, 24-H, 8-H), 3.97–4.03 (m, 1H, 9-H), 4.92–5.01 (m, 1H, 20-H), 5.38–5.51 (m, 1H, 15-H), 6.31 (d, J=2.0 Hz, 1H, 6-H), 6.41 (d, J=2.0 Hz, 1H, 4-H), 6.73 (dd, J=14.0 Hz, 10.6 Hz, 1H, 21-H), 8.08 ppm (br d, J=10.6 Hz, 1H, NH); ¹³C NMR (100 MHz, CDCl₃): δ=−4.6 (Si(CH₃)₂), −4.6 (Si(CH₃)₂), −3.8 (Si(CH₃)₂), −3.7 (Si(CH₃)₂), 11.3 (16-CH₃), 12.4 (23-CH₃), 13.0 (CH(CH₃)₂), 14.1 (C27), 16.7 (10-CH₃), 17.9 (CH(CH₃)₂), 17.9 (Si(C(CH₃)₃)), 18.1 (CH(CH₃)₂), 18.4 (18-CH₃), 19.4 (C26), 23.3 (C14), 23.7 (C11), 25.9 (Si(C(CH₃)₃)), 26.1 (Si(C(CH₃)₃)), 32.6 (C19), 34.7 (C25), 37.6 (C18), 38.1 (C16), 38.6 (C8), 40.7 (C10), 45.6 (C23), 55.2 (OCH₃), 55.7 (OCH₃), 74.9 (C17), 76.2 (C9), 77.2 (C24), 79.7 (C=C), 81.2 (C=C), 96.6 (C4), 108.3 (C6), 110.9 (C20), 118.2 (C2), 123.4 (C21), 139.4 (C7), 157.2 (C5), 160.2 (C3), 167.4 (C1), 170.9 ppm (C22); HRMS (ESI): [M+Na]⁺ calcd for C₅₄H₉₇NaNO₈Si₃ 994.64142, found 994.64053.

Deprotected enamide macrolactone (22): The HF-pyridine complex (70 % HF, 0.3 mL) was added dropwise to a stirred solution of the enamide **21** (10 mg, 0.01 mmol) in THF (0.4 mL, in a plastic test tube) at −80 °C. The reaction mixture was allowed to warm to −10 °C. After 2 h, the mixture was partitioned between an ice-cooled mixture of EtOAc (20 mL) and saturated aqueous NaHCO₃ solution (20 mL). The organic layer was separated and the H₂O layer extracted with EtOAc (2×20 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by flash chromatography (CH₂Cl₂/MeOH, 95:5→9:1) to give triol **22** (4.4 mg; 75 %). TLC (CH₂Cl₂/MeOH, 9:1): R_f=0.47; [α]_D²⁰=−3.3 (c=0.4, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ=0.81 (d, J=6.8 Hz, 3H, 18-CH₃), 0.90–0.98 (m, 6H, 27-H, 10-CH₃), 1.10 (d, J=7.1 Hz, 3H, 16-CH₃), 1.16 (d, J=7.3 Hz, 3H, 23-CH₃), 1.28–1.39 (m, 2H, 25-H, 26-H), 1.41–1.51 (m, 2H, 25-H, 26-H), 1.58–1.67 (m, 2H, 19-H, OH), 1.90–2.02 (m, 4H, 18-H, 19-H, 11-H, OH), 2.05–2.14 (m, 1H, 16-H), 2.29–2.40 (m, 2H, 8-H, 10-H), 2.46–2.63 (m, 3H, 14-H, 11-H), 2.71–2.79 (m, 1H, 23-H), 2.85 (br s, 1H, OH), 3.29–3.26 (m, 1H, 8-H), 3.45–3.49 (m, 1H, 17-H), 3.78 (s, 3H, OCH₃), 3.80 (s, 3H, OCH₃), 3.83–3.90 (m, 2H, 9-H, 24-H), 5.10–5.19 (m, 1H, 20-H), 5.46–5.52 (m, 1H, 15-H), 6.35 (d, J=2.0 Hz, 1H, 6-H), 6.41 (d, J=2.0 Hz, 1H, 4-H), 6.75 (dd, J=14.2, 10.4 Hz, 1H, 21-H), 7.52 ppm (d, J=10.4 Hz, 1H, NH); HRMS (ESI): [M+Na]⁺ calcd for C₃₃H₄₉NaNO₈ 610.33504, found 610.33433.

Enamide analogue (23): Lindlar's catalyst (5 wt % Pd on CaCO₃, poisoned with lead, 4.0 mg, 100 wt %) was added to a stirred solution of diyne **22** (4.0 mg, 0.007 mmol) in EtOAc (2 mL) containing quinoline (1.4 mg, 0.011 mmol). The reaction was placed under H₂ atmosphere and stirred for 1 h. The reaction mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. The residue was purified by flash chromatography (CH₂Cl₂/MeOH, 95:5→9:1) to give enamide **23** as a colourless oil (3.4 mg, 85 %). TLC (CH₂Cl₂/MeOH, 9:1): R_f=0.52; [α]_D²⁰=−4.3 (c=0.3, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ=0.83 (d, J=6.8 Hz, 3H, 18-CH₃), 0.93 (t, J=6.8 Hz, 3H, 27-H), 0.98 (d, J=6.8 Hz, 3H, 16-CH₃), 1.05 (d, J=6.8 Hz, 3H, 10-CH₃), 1.16 (d, J=7.3 Hz, 3H, 23-CH₃), 1.28–1.40 (m, 2H, 25-H, 26-H), 1.42–1.71 (m, 4H, 25-H, 26-H, 19-H, OH), 1.88–1.99 (m, 4H, 18-H, 19-H, 11-H, 14-H), 2.07–2.21 (m, 1H, 16-H), 2.27–2.37 (m, 2H, 8-H, 10-H), 2.37–2.50 (m, 1H, 11-H), 2.70–3.00 (m, 4H, 23-H, 14-H, 8-H, OH), 3.45–3.52 (m, 1H, 17-H), 3.71–3.81 (m, 7H, OCH₃, 24-H), 3.85–3.91 (m, 1H, 9-H), 5.09–5.19 (m, 1H, 20-H), 5.40 (dd, J=9.9, 4.0 Hz, 1H, 15-H), 5.48–5.54 (m, 2H, 12-H, 13-H), 6.33–6.36 (m, 2H, 6-H, 4-H), 6.74 (dd, J=14.2, 10.4 Hz, 1H, 21-H), 7.52 ppm (d, J=10.4 Hz, 1H, NH); HRMS (ESI): [M+Na]⁺ calcd for C₃₃H₅₁NaNO₈ 612.35069, found 612.35104.

(1S)-1-[(1R,2R,3R)-2-[(*tert*-Butyl(dimethyl)silyl]oxy]-6-[(3,4-dimethoxybenzyl)oxy]-1,3-dimethylhexyl]pent-3-ynyl 2,4-dimethoxy-6-[(2R,3S)-3-methyl-2-[(triisopropylsilyl)oxy]hept-5-ynyl]benzoate (41): A solution of diol **37** (470 mg, 1.24 mmol) in anhydrous DMF (2.5 mL) was stirred in the presence of sodium hydride (60 % wt in mineral oil, 124 mg, 3.1 mmol, 2.5 equiv) at 0 °C for 10 min and for a further 1 h at room temperature. CDI (390 mg, 2.4 mmol) was added to a solution of acid **38** (917 mg, 2.0 mmol) in anhydrous DMF (3.5 mL) in a separate flask and the reaction mixture was then allowed to stir for 4 h at 50 °C. Then, the solution of the imidazolide derivative **39** (analysed by LC–MS) was

cooled to 0°C and added to the above solution of the disodium salt of diol **37** at 0°C. The mixture was allowed to warm to room temperature and stirred for three days. After the addition of saturated NH₄Cl solution, the mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with 1 M HCl, saturated NaHCO₃ and saturated NaCl solution, dried over MgSO₄, filtered and concentrated in vacuo to provide 1.01 g of crude hydroxyester **40**, which was used in the next step without further purification.

A solution of the crude hydroxyester **40** (1.01 g, 1.23 mmol) in CH₂Cl₂ (10 mL) was cooled to –50°C, then 2,6-lutidine (0.58 mL, 4.9 mmol) followed by *tert*-butyldimethylsilyltriflate (TBSOTf; 0.46 mL, 2.0 mmol) were added. The reaction mixture was allowed to warm to room temperature and stirred for 2 h before it was treated with water. After separation of the layers, the aqueous layer was extracted with CH₂Cl₂. The combined organic extracts were washed with 1 M HCl, saturated NaHCO₃ and saturated NaCl solution, dried over MgSO₄, filtered and concentrated in vacuo. Flash chromatography (petroleum ether/EtOAc, 10:1 → 4:1) afforded ester **41** (0.778 g, 67% for 2 steps, based on diol **37**) as a colourless oil. Besides ester **41**, some unreacted imidazolide derivative **39** (295 mg, 30%) was isolated. TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.46, [α]_D²⁰ = +24.8 (*c* 2.4, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = –0.01, 0.02 (2 s, 6H, Si(CH₃)₂), 0.83–0.89 (m, 12H, Si(C(CH₃)₃), 3'''-CH₃), 0.89–0.97 (m, 27H, 1'''-CH₃, 3'-CH₃, Si(CH(CH₃)₂)₃), 1.04–1.11 (m, 1H, 5'''-H), 1.45–1.58 (m, 3H, 4'''-H, 5'''-H), 1.66 (t, *J* = 2.3 Hz, 3H, C=CCH₃), 1.71 (t, *J* = 2.3 Hz, 3H, C=CCH₃), 1.80–1.91 (m, 1H, 3'-H), 1.96–2.05 (m, 2H, 3'''-H, 4'-H), 2.07–2.20 (m, 2H, 1'''-H, 4'-H), 2.49–2.71 (m, 4H, 2''-H, 1'-H), 3.34–3.40 (m, 2H, CH₂ODMB), 3.50–3.54 (m, 1H, CH(OTBS)), 3.69 (s, 3H, OCH₃), 3.73 (s, 3H, OCH₃), 3.80–3.84 (m, 6H, OCH₃ of DMB), 4.21–4.36 (m, 1H, CH(OTIPS)), 4.37 (s, 2H, CH₂ of DMB), 4.93–5.00 (m, 1H, 1'-H), 6.24 (d, *J* = 2.3 Hz, 1H, 5-H), 6.43 (d, *J* = 2.3 Hz, 3-H), 6.74–6.85 ppm (m, 3H, aryl H of DMB); ¹³C NMR (100 MHz, CDCl₃): δ = –3.7 (Si(CH₃)₂), –3.6 (Si(CH₃)₂), 3.5 (C=CCH₃), 3.5 (C=CCH₃), 10.3 (1'''-CH₃), 12.9 (CH(CH₃)₂), 14.6 (3'-CH₃), 16.5 (Si(C(CH₃)₃)), 18.0 (CH(CH₃)₂), 18.2 (CH(CH₃)₂), 18.5 (3'''-CH₃), 22.1 (C=CCH₂), 22.1 (C=CCH₂), 26.1 (Si(C(CH₃)₃)), 28.0 (C5'''), 28.7 (C4'''), 36.2 (C1'), 37.5 (C3'''), 37.8 (C1'''), 38.8 (C3'), 55.2 (OCH₃), 55.6 (OCH₃), 55.8 (OCH₃), 55.9 (OCH₃), 70.7 (C6''), 72.8 (CH₂ of DMB), 74.6 (CH₃C=C), 74.9 (CH₃C=C), 75.2 (C2'), 76.0 (CH₂C=C), 76.6 (CH₂C=C), 77.9 (C2''), 78.1 (C1''), 96.7 (C3), 107.0 (C5), 110.8 (Ar of DMB), 111.0 (Ar of DMB), 117.9 (C1), 120.2 (Ar of DMB), 131.2 (Ar of DMB), 139.0 (C6), 148.4 (Ar of DMB), 148.9 (Ar of DMB), 157.8 (C4), 160.7 (C2), 167.7 ppm (CO₂R); HRMS (ESI): [*M*+Na]⁺ calcd for C₅₄H₈₈NaO₉Si₂ 959.58591, found 959.58513.

(3*S*,8*S*,9*R*)-3-[(1*R*,2*R*,3*R*)-2-[(*tert*-Butyl(dimethyl)silyl]oxy]-6-[(3,4-dimethoxybenzyl)oxy]-1,3-dimethylhexyl]-12,14-dimethoxy-8-methyl-9-[(triisopropylsilyl)oxy]-5,6-didehydro-3,4,7,8,9,10-hexahydro-1*H*-2-benzoxacyclododecin-1-one (42): A solution of (tBuO)₃W=CCMe₃ (**6**) (32.8 mg, 0.069 mmol) in toluene (1.0 mL) was added to a solution of ester **41** (650 mg, 0.69 mmol) in toluene (81 mL) and the mixture was stirred at 85°C for 3 h. For workup, the solvent was evaporated and the residue purified by flash chromatography (petroleum ether/EtOAc, 10:1) to give macrolactone **42** as an amorphous solid (553 mg, 90%). TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.63; [α]_D²⁰ = –19.0 (*c* = 2.4, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.01–0.06 (m, 6H, Si(CH₃)₂), 0.87–0.97 (m, 36H, 18-CH₃, 10-CH₃, Si(C(CH₃)₃), Si(CH(CH₃)₂)₃), 1.03 (d, *J* = 6.8 Hz, 3H, 16-CH₃), 1.40–1.52 (m, 2H, 20-H), 1.60–1.85 (m, 4H, 19-H, 11-H, 16-H), 1.89–1.98 (m, 1H, 18-H), 2.09–2.19 (m, 1H, 11-H), 2.35–2.51 (m, 4H, 14-H, 8-H, 10-H), 3.37 (dd, *J* = 6.4, 6.4 Hz, 2H, 21-H), 3.48 (dd, *J* = 4.3, 4.3 Hz, 1H, 17-H), 3.71–3.79 (m, 7H, 8-H, OCH₃), 3.84–3.87 (m, 6H, OCH₃ of DMB), 3.98–4.02 (m, 1H, 9-H), 4.40 (s, 2H, CH₂ of DMB), 5.35–5.50 (m, 1H, 15-H), 6.30 (d, *J* = 2.0 Hz, 1H, 6-H), 6.40 (d, *J* = 2.0 Hz, 1H, 4-H), 6.78–6.88 ppm (m, 3H, Ar of DMB); ¹³C NMR (100 MHz, CDCl₃): δ = –4.0 (Si(CH₃)₂), –3.7 (Si(CH₃)₂), 11.2 (16-CH₃), 12.9 (CH(CH₃)₂), 16.7 (10-CH₃), 17.8 (CH(CH₃)₂), 18.0 (CH(CH₃)₂), 18.3 (18-CH₃), 23.3 (C=CCH₂), 23.5 (C=CCH₂), 26.1 (Si(C(CH₃)₃)), 27.7 (C20), 28.4 (C19), 37.4 (2C, C16, C18), 38.5 (C8), 40.3 (C10), 55.1 (OCH₃), 55.7 (OCH₃), 55.7 (OCH₃), 55.8 (OCH₃), 70.3 (C21), 72.7 (CH₂ of DMB), 76.0 (C15), 77.2 (C17), 79.6 (C9), 81.2 (CH₂C=C), 96.6 (C3), 108.2 (C6), 110.8 (Ar of DMB), 110.9 (Ar of DMB), 118.1 (C2), 120.1 (Ar of DMB), 131.1

(Ar of DMB), 139.3 (C7), 148.4 (Ar of DMB), 148.9 (Ar of DMB), 157.2 (C5), 160.2 (C3), 167.3 ppm (CO₂R); HRMS (ESI): [*M*+Na]⁺ calcd for C₅₀H₈₂NaO₅Si₂ 905.53896, found 905.53829.

Alcohol 43: DDQ (194 mg, 0.85 mmol, 1.4 equiv) was added to a cooled (0°C) solution of DMB ether **42** (540 mg, 0.61 mmol) in a mixture of CH₂Cl₂/pH 7 phosphate buffer solution (20:1, 32 mL). The mixture was allowed to warm to room temperature and stirred for 40 min. Then it was treated with saturated NaHCO₃ solution and the layers were separated. The aqueous layer was extracted with CH₂Cl₂. The combined organic extracts were washed with saturated NaHCO₃ and saturated NaCl solution, dried over MgSO₄, filtered and concentrated in vacuo. Flash chromatography (petroleum ether/EtOAc, 4:1) afforded alcohol **43** (435 mg, 97%) as an amorphous solid. TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.42; [α]_D²⁰ = –28.0 (*c* = 4.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.02, 0.06 (2 s, 6H, Si(CH₃)₂), 0.86–0.96 (m, 36H, 18-CH₃, 16-CH₃, Si(C(CH₃)₃), Si(CH(CH₃)₂)₃), 1.02 (d, *J* = 7.1 Hz, 3H, 10-CH₃), 1.05–1.10 (m, 1H, 20-H), 1.38–1.51 (m, 2H, 20-H, 19-H), 1.55–1.73 (m, 3H, 19-H, 11-H, OH), 1.76–1.82 (m, 1H, 11-H), 1.86–1.97 (m, 1H, 16-H), 2.10–2.18 (m, 1H, 18-H), 2.34–2.51 (m, 4H, 8-H, 14-H, 10-H), 3.50 (dd, *J* = 4.3, 4.3 Hz, 1H, 17-H), 3.55 (dd, *J* = 6.3, 6.3 Hz, 2H, 21-H), 3.70–3.78 (m, 7H, 8-H, OCH₃), 3.76 (s, 3H, OCH₃), 3.96–4.02 (m, 1H, 9-H), 5.37–5.50 (m, 1H, 15-H), 6.31 (d, *J* = 2.3 Hz, 1H, 6-H), 6.40 ppm (s, *J* = 2.3 Hz, 1H, 4-H); ¹³C NMR (100 MHz, CDCl₃): δ = –4.0 (Si(CH₃)₂), –3.7 (Si(CH₃)₂), 11.4 (16-CH₃), 12.9 (CH(CH₃)₂), 16.7 (10-CH₃), 17.8 (Si(C(CH₃)₃)), 18.0 (CH(CH₃)₂), 18.3 (18-CH₃), 23.2 (C14), 23.4 (C11), 26.1 (Si(C(CH₃)₃)), 28.0 (C20), 30.7 (C19), 37.4 (C16), 37.4 (C18), 38.6 (C8), 40.3 (C10), 55.1 (OCH₃), 55.8 (OCH₃), 62.9 (C21), 76.0 (C15), 76.7 (C17), 77.3 (C=C), 79.6 (C9), 81.2 (C12), 96.7 (C4), 108.3 (C2), 118.1 (C6), 139.4 (C7), 157.2 (C5), 160.2 (C3), 167.4 ppm (C1); HRMS (ESI): [*M*+Na]⁺ calcd for C₄₁H₇₂NaO₅Si₂ 755.47088, found 755.47080.

Aldehyde 44: A solution of Dess–Martin periodinane (15% wt, 1.02 mL, 0.49 mmol) was added to a cooled (0°C) solution of alcohol **43** (198 mg, 0.27 mmol) in CH₂Cl₂ (6 mL). After stirring for 0.5 h at 0°C and for 2 h at room temperature, the reaction mixture was concentrated, loaded on a flash column and eluted with petroleum ether/EtOAc (4:1) to give 188 mg (95%) of aldehyde **44**, which was used directly in the next reaction. TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.69.

Alkyne 46: Diethyl-1-diazo-2-oxopropylphosphonate^[38] (**45**) (124 mg, 0.52 mmol, 2 equiv) was added to a solution of aldehyde **45**, which was obtained in the previous step (188 mg, 0.26 mmol), and K₂CO₃ (122 mg, 0.88 mmol, 3.4 equiv) in MeOH (5 mL) followed by stirring of the mixture for 12 h at room temperature. The reaction mixture was diluted with Et₂O (50 mL) and washed with an aqueous solution (5%) of NaHCO₃ (20 mL). The layers were separated and the organic layer dried over Na₂SO₄. After filtration and evaporation of the solvent, the residue was purified by flash chromatography (EtOAc/petroleum ether, 1:10) to give 179 mg (97%) of alkyne **46** as an amorphous solid. TLC (petroleum ether/EtOAc, 4:1): *R*_f = 0.78; [α]_D²⁰ = –32.2 (*c* 2.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.03–0.07 (m, 6H, Si(CH₃)₂), 0.86–0.99 (m, 36H, 16-CH₃, 18-CH₃, Si(C(CH₃)₃), Si(CH(CH₃)₂)₃), 1.04 (d, *J* = 7.1 Hz, 3H, 10-CH₃), 1.20–1.32 (m, 1H, 20-H), 1.61–1.71 (m, 1H, 20-H), 1.75–1.84 (m, 1H, 16-H), 1.87–1.98 (m, 3H, 19-H, C=CH), 2.02–2.28 (m, 3H, 10-H, 11-H, 18-H), 2.36–2.47 (m, 4H, 8-H, 14-H, 11-H), 3.52 (dd, *J* = 4.3, 4.3 Hz, 1H, 17-H), 3.71–3.79 (m, 7H, 8-H, OCH₃), 3.78 (s, 3H, OCH₃), 3.97–4.02 (m, 1H, 9-H), 5.40–5.52 (m, 1H, 15-H), 6.31 (d, *J* = 2.0 Hz, 1H, 6-H), 6.41 ppm (s, *J* = 2.0 Hz, 1H, 4-H); ¹³C NMR (100 MHz, CDCl₃): δ = –4.0 (Si(CH₃)₂), –3.6 (Si(CH₃)₂), 11.3 (16-CH₃), 13.0 (CH(CH₃)₂), 16.4 (10-CH₃), 16.5 (C20), 17.8 (CH(CH₃)₂), 18.0 (CH(CH₃)₂), 18.4 (18-CH₃), 23.2 (C14), 23.3 (C11), 26.1 (Si(C(CH₃)₃)), 30.8 (C19), 36.5 (C18), 37.5 (C16), 38.6 (C8), 40.4 (C10), 55.1 (OCH₃), 55.7 (OCH₃), 68.4 (C22), 74.8 (C=C), 75.6 (C15), 77.2 (C17), 79.6 (C=C), 81.2 (C=C), 84.5 (C9), 96.6 (C4), 108.2 (C2), 118.1 (C6), 139.4 (C7), 157.2 (C5), 160.2 (C3), 167.3 ppm (C1); HRMS (ESI): [*M*+Na]⁺ calcd for C₄₂H₇₀NaO₆Si₂ 749.46031, found 749.46039.

(E)-Vinyl iodide 47: [Cp₂Zr(H)Cl] (38 mg, 0.14 mmol) was added to a solution of alkyne **46** (51 mg, 0.07 mmol) in THF (1.5 mL) at 0°C and the resulting mixture was stirred for 2 h at that temperature. A solution of I₂ (0.28 mL, 0.5 M in THF, 0.14 mmol) was then added dropwise and stirring

was continued for 2 h. The reaction was quenched with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ solution (5 mL), and the mixture was repeatedly extracted with Et_2O . The combined organic layers were dried (MgSO_4), filtered and evaporated. The residue was purified by flash chromatography (petroleum ether/ EtOAc , 4:1) to give (*E*)-vinyl iodide **47** as an amorphous solid (66 mg, 95%). TLC (petroleum ether/ EtOAc , 4:1): $R_f=0.77$; $[\alpha]_D^{20}=-21.0$ ($c=3.6$, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3): $\delta=0.03$ – 0.07 (m, 6H, $\text{Si}(\text{CH}_3)_2$), 0.84 – 0.97 (m, 36H, 16- CH_3 , 18- CH_3 , $\text{Si}(\text{C}(\text{CH}_3)_3$), $\text{Si}(\text{CH}(\text{CH}_3)_2$), 1.04 (d, $J=6.8$ Hz, 3H, 10- CH_3), 1.20 – 1.26 (m, 1H, 20-H), 1.43 – 1.54 (m, 1H, 19-H), 1.64 – 1.72 (m, 1H, 20-H), 1.74 – 1.82 (m, 1H, 16-H), 1.87 – 1.98 (m, 2H, 19-H, 18-H), 2.02 – 2.20 (m, 2H, 10-H, 11-H), 2.37 – 2.48 (m, 4H, 8-H, 14-H, 11-H), 3.52 (dd, $J=4.3$, 4.3 Hz, 1H, 17-H), 3.72 – 3.81 (m, 7H, 8-H, OCH_3), 3.97 – 4.02 (m, 1H, 9-H), 5.39 – 5.44 (m, 1H, 15-H), 5.90 (d, $J=14.4$ Hz, 1H, 22-H), 6.33 (d, $J=2.0$ Hz, 1H, 6-H), 6.36 – 6.45 ppm (m, 2H, 4-H, 21-H); ^{13}C NMR (100 MHz, CDCl_3): $\delta=-4.0$ ($\text{Si}(\text{CH}_3)_2$), -3.6 ($\text{Si}(\text{CH}_3)_2$), 11.5 (16- CH_3), 13.0 ($\text{CH}(\text{CH}_3)_2$), 16.4 (10- CH_3), 16.5 (C20), 17.9 ($\text{CH}(\text{CH}_3)_2$), 18.1 ($\text{CH}(\text{CH}_3)_2$), 18.4 (18- CH_3), 23.2 (C14), 23.2 (C11), 26.1 ($\text{Si}(\text{C}(\text{CH}_3)_3$), 30.8 (C19), 34.1 (C20), 37.4 (C18), 37.5 (C16), 38.6 (C8), 40.0 (C10), 55.2 (OCH_3), 55.8 (OCH_3), 74.5 (C22), 75.4 (C15), 77.2 (C17), 79.6 ($\text{C}=\text{C}$), 81.4 (C9), 96.6 (C4), 108.4 (C2), 118.0 (C6), 139.4 (C7), 146.6 (C21), 157.3 (C5), 160.3 (C3), 167.3 ppm (C1); HRMS (ESI): $[M+\text{Na}]^+$ calcd for $\text{C}_{42}\text{H}_{71}\text{NaO}_6\text{Si}_2$ 877.37261, found 877.37329.

Enamide 48: A Schlenk tube was charged with CuI (14.0 mg, 0.075 mmol, 1 equiv), amide **20** (39 mg, 0.15 mmol, 2 equiv) and Cs_2CO_3 (62 mg, 0.19 mmol, 2.5 equiv). The tube was evacuated and backfilled with argon. *N,N'*-Dimethylethylenediamine (16.0 μL , 0.15 mmol, 2 equiv), vinyl iodide **47** (64 mg, 0.075 mmol) and THF (1.0 mL) were added under argon. The Schlenk tube was closed with a glass stopper, immersed in a preheated to 60°C oil bath and the reaction mixture was stirred for 14 h. After the resulting pale-blue suspension was allowed to reach room temperature, ethyl acetate (5 mL) was added and the reaction mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (petroleum ether/ EtOAc , 10:1→4:1) to give enamide **48** as an amorphous solid (63 mg, 85%). TLC (petroleum ether/ EtOAc , 4:1): $R_f=0.72$; $[\alpha]_D^{20}=-23.9$ ($c=1.3$, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3): $\delta=0.02$ – 0.07 (m, 6H, $\text{Si}(\text{CH}_3)_2$), 0.08 – 0.10 (m, 6H, $\text{Si}(\text{CH}_3)_2$), 0.85 – 1.01 (m, 48H, 24- CH_3 , 28-H, 16- CH_3 , $\text{Si}(\text{C}(\text{CH}_3)_3$), $\text{Si}(\text{CH}(\text{CH}_3)_2$), 1.02 – 1.10 (m, 6H, 18- CH_3 , 10- CH_3), 1.16 – 1.27 (m, 3H, 20-H, 27-H), 1.30 – 1.52 (m, 5H, 26-H, 27-H, 18-H, 19-H), 1.74 – 1.83 (m, 1H, 16-H), 1.86 – 1.99 (m, 2H, 10-H, 11-H), 2.04 – 2.19 (m, 2H, 19-H, 11-H), 2.36 – 2.55 (m, 5H, 8-H, 14-H, 24-H), 3.43 – 3.48 (m, 1H, 17-H), 3.71 – 3.79 (m, 7H, OCH_3 , 25-H), 3.97 – 4.03 (m, 1H, 9-H), 4.94 – 5.03 (m, 1H, 21-H), 5.35 – 5.49 (m, 1H, 15-H), 6.31 (d, $J=2.0$ Hz, 1H, 6-H), 6.41 (d, $J=2.0$ Hz, 1H, 4-H), 6.73 (dd, $J=14.2$, 10.6 Hz, 1H, 22-H), 8.08 ppm (br d, $J=10.6$ Hz, 1H, NH); ^{13}C NMR (100 MHz, CDCl_3): $\delta=-4.6$ ($\text{Si}(\text{CH}_3)_2$), -4.6 ($\text{Si}(\text{CH}_3)_2$), -3.8 ($\text{Si}(\text{CH}_3)_2$), -3.7 ($\text{Si}(\text{CH}_3)_2$), 11.2 (16- CH_3), 12.6 (24- CH_3), 13.0 ($\text{CH}(\text{CH}_3)_2$), 14.1 (C28), 16.5 (10- CH_3), 17.9 ($\text{Si}(\text{C}(\text{CH}_3)_3$), 17.9 ($\text{CH}(\text{CH}_3)_2$), 18.1 ($\text{CH}(\text{CH}_3)_2$), 18.4 (18- CH_3), 19.3 (C27), 23.3 (C14), 23.6 (C11), 25.9 ($\text{Si}(\text{C}(\text{CH}_3)_3$), 26.2 ($\text{Si}(\text{C}(\text{CH}_3)_3$), 27.7 (C20), 32.5 (C19), 34.7 (C26), 37.0 (C18), 37.6 (C16), 38.6 (C8), 40.6 (C10), 45.6 (C24), 55.2 (OCH_3), 55.7 (OCH_3), 75.0 (C17), 76.1 (C9), 76.8 (C15), 77.2 (C25), 79.6 ($\text{C}=\text{C}$), 81.2 ($\text{C}=\text{C}$), 96.7 (C4), 108.3 (C6), 112.2 (C21), 118.2 (C2), 122.6 (C22), 139.4 (C7), 157.2 (C5), 160.2 (C3), 167.4 (C1), 171.0 ppm (C23); HRMS (ESI): $[M+\text{Na}]^+$ calcd for $\text{C}_{53}\text{H}_{99}\text{NNaO}_5\text{Si}_3$ 1008.65707, found 1008.65733.

Deprotected macrolactone 49: HF-pyridine complex (70% HF, 0.3 mL) was added dropwise to a stirred solution of the enamide **48** (12 mg, 0.012 mmol) in THF (0.4 mL, in a plastic test tube) at -80°C . The reaction mixture was allowed to warm to -10°C . After 2 h the mixture was partitioned between an ice-cooled mixture of EtOAc (20 mL) and saturated aqueous NaHCO_3 solution (20 mL). The organic layer was separated and the H_2O layer extracted with EtOAc (2×20 mL). The combined organic layers were dried over MgSO_4 , filtered and concentrated in vacuo. The residue was purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 95:5 → 9:1) to give 6.1 mg (85%) of triol **49**. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9:1): $R_f=0.38$; $[\alpha]_D^{20}=-4.2$ ($c=1.2$, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3): $\delta=0.84$ (d, $J=6.8$ Hz, 3H, 18- CH_3), 0.91 (t, $J=7.1$ Hz, 3H, 28-H), 0.99 (d, $J=7.1$ Hz, 3H, 10- CH_3), 1.10 (d, $J=7.1$ Hz, 3H, 16- CH_3), 1.14 (d, $J=7.1$ Hz,

3H, 24- CH_3), 1.24 – 1.50 (m, 5H, 26-H, 27-H, 20-H), 1.55 – 1.77 (m, 4H, 19-H, 20-H, OH), 1.89 – 2.02 (m, 3H, 18-H, 19-H, 11-H), 2.05 – 2.20 (m, 3H, 16-H, 24-H, 11-H), 2.24 – 2.33 (m, 1H, 8-H), 2.46 – 2.62 (m, 3H, 14-H, 10-H, OH), 2.73 – 2.82 (m, 1H, 14-H), 3.09 (br s, 1H, OH), 3.27 (dd, $J=13.8$ Hz, 2.7 Hz, 1H, 8-H), 3.38 – 3.44 (m, 1H, 17-H), 3.75 – 3.89 (m, 8H, OCH_3 , 9-H, 25-H), 5.01 – 5.10 (m, 1H, 21-H), 5.42 – 5.50 (m, 1H, 15-H), 6.34 (d, $J=2.0$ Hz, 1H, 6-H), 6.40 (d, $J=2.0$ Hz, 1H, 4-H), 6.70 (dd, $J=14.2$, 10.4 Hz, 1H, 22-H), 7.68 ppm (d, $J=10.4$ Hz, 1H, NH); HRMS (ESI): $[M+\text{Na}]^+$ calcd for $\text{C}_{34}\text{H}_{51}\text{NNaO}_8$ 624.35069, found 624.35092.

Enamide analogue 50: A 5-mL round-bottom flask was charged with diyne **49** (3.0 mg, 0.005 mmol) and stirred with a stir bar. EtOAc (2 mL) and quinoline (1.0 mg, 0.08 mmol) were added with stirring. This was followed by the addition of Lindlar's catalyst (5 wt % Pd on CaCO_3 , poisoned with lead, 3 mg, 100 wt %). The reaction was placed under H_2 atmosphere and stirred for 1 h. The reaction mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. The residue was purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 95:5 → 9:1) to give enamide **50** as a colourless oil (2.7 mg, 90%). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9:1): $R_f=0.41$; $[\alpha]_D^{20}=-5.6$ ($c=0.2$, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3): $\delta=0.84$ – 0.89 (m, 6H, 28-H, 18- CH_3), 1.01 – 1.06 (m, 6H, 10- CH_3 , 16- CH_3), 1.14 (d, $J=7.1$ Hz, 3H, 24- CH_3), 1.21 – 1.31 (m, 4H, 26-H, 27-H, 20-H), 1.34 – 1.49 (m, 2H, 26-H, 27-H), 1.57 (br s, 1H, OH), 1.63 – 1.75 (m, 2H, 18-H, 19-H), 1.81 – 2.07 (m, 5H, 10-H, 11-H, 16-H, 19-H, 8-H), 2.15 – 2.24 (m, 1H, 14-H), 2.25 – 2.40 (m, 1H, 24-H), 2.58 (br s, 1H, OH), 2.74 – 2.86 (m, 1H, 11-H), 2.92 – 3.00 (m, 1H, 8-H), 2.82 (dt, $J=14.3$, 11.5 Hz, 1H, 14-H), 3.29 – 3.39 (m, 2H, 17-H, OH), 3.69 – 3.76 (m, 4H, 25-H, OCH_3), 3.77 – 3.83 (m, 4H, 9-H, OCH_3), 5.10 – 5.19 (m, 1H, 21-H), 5.36 (dd, $J=10.2$, 3.2 Hz, 1H, 15-H), 5.41 – 5.56 (m, 2H, 12-H, 13-H), 6.32 – 6.36 (m, 2H, 6-H, 4-H), 6.76 (dd, $J=14.2$ Hz, 10.6 Hz, 1H, 22-H), 7.69 ppm (d, $J=10.4$ Hz, 1H, NH); HRMS (ESI): $[M+\text{Na}]^+$ calcd for $\text{C}_{34}\text{H}_{53}\text{NO}_8\text{Na}$ 626.36689, found 626.36672.

Oxazinane-4-one 51: a) *ortho*-Demethylation: A solution of enamide **49** (18 mg, 0.018 mmol) in CH_2Cl_2 (2 mL) was treated with BCl_3 (72 μL , 1.0 M in CH_2Cl_2 , 0.072 mmol, 4 equiv) at -80°C . The reaction was stirred for 2 h at -80°C before a saturated solution of NaOAc (5 mL) was added. After separation of the layers, the aqueous phase was extracted twice with CH_2Cl_2 . The combined organic layers were washed with H_2O , saturated NaCl solution, dried over MgSO_4 , filtered and concentrated in vacuo to give 17 mg of crude 2-hydroxy-4-methoxybenzoate which was used in the next step without further purification.

b) Global deprotection: HF-pyridine complex (70% HF, 0.6 mL) was added dropwise to a stirred solution of the crude 2-hydroxy-4-methoxybenzoate (17 mg) in THF (0.8 mL, in a plastic test tube) at -80°C dropwise. The reaction mixture was allowed to warm to -10°C . After 2 h, the mixture was partitioned between an ice-cooled mixture of EtOAc (20 mL) and saturated aqueous NaHCO_3 solution (20 mL). The organic layer was separated and the H_2O layer extracted with EtOAc (2×20 mL). The combined organic layers were dried over MgSO_4 , filtered and concentrated in vacuo. The residue was purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 95:5 → 9:1) to give 9.2 mg (87% for 2 steps) of triol **51**. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9:1): $R_f=0.38$; $[\alpha]_D^{20}=+14.0$ ($c=0.4$, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3): $\delta=0.82$ (d, $J=6.6$ Hz, 3H, 18- CH_3), 0.91 – 0.97 (m, 6H, 28-H, 16- CH_3), 1.04 (d, $J=7.1$ Hz, 3H, 10- CH_3), 1.19 (d, $J=7.3$ Hz, 3H, 24- CH_3), 1.27 – 1.75 (m, 10H, 19-H, 26-H, 27-H, 20-H, 21-H), 1.95 – 2.21 (m, 4H, 18-H, 16-H, 11-H, OH), 2.28 – 2.36 (m, 3H, 8-H, 24-H, OH), 2.54 – 2.73 (m, 3H, 14-H, 10-H, 11-H), 2.78 – 2.86 (m, 1H, 14-H), 3.53 (d, $J=8.8$ Hz, 1H, 17-H), 3.69 – 3.78 (m, 2H, 25-H, 8-H), 3.80 (s, 3H, OCH_3), 3.91 – 3.99 (m, 1H, 9-H), 4.79 (t, $J=5.6$ Hz, 1H, 22-H), 5.37 – 5.43 (m, 1H, 15-H), 6.38 – 6.40 (m, 2H, 4-H, 6-H), 6.76 (br s, 1H, NH), 11.1 ppm (br s, 1H, 3-OH); ^{13}C NMR (100 MHz, CDCl_3): $\delta=7.9$ (16- CH_3), 12.0 (24- CH_3), 14.0 (C28), 16.4 (18- CH_3), 16.7 (10- CH_3), 18.8 (C27), 20.9 , 21.7 (C14), 22.3 (C11), 29.7 (C20), 32.5 (C19), 33.3 (C21), 35.6 (C26), 36.0 , 36.3 (C18), 37.8 (C16), 38.2 (C8), 40.0 (C24), 55.4 (OCH_3), 71.0 (C25), 75.1 (C9), 76.2 (C15), 77.2 ($\text{C}=\text{C}$), 79.0 ($\text{C}=\text{C}$), 83.0 (C22), 84.0 , 99.4 (C4), 110.2 (C6), 142.0 (C7), 162.0 (C5), 163.0 (C3), 170.2 (C1), 175.0 (C23); HRMS (ESI): $[M+\text{Na}]^+$ calcd for $\text{C}_{33}\text{H}_{49}\text{NaNO}_8$ 610.33504, found 610.33543.

Oxazinan-4-one 52: A 10-mL round-bottom flask was charged with alkyne **51** (9.0 mg, 0.015 mmol) and stirred with a stir bar. EtOAc (5 mL) and quinoline (3.0 mg, 0.024 mmol) were added with stirring. This was followed by the addition of Lindlar's catalyst (5 wt % Pd on CaCO₃, poisoned with lead, 9 mg, 100 wt %). The reaction was placed under H₂ atmosphere and stirred for 1 h. The reaction mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. The residue was purified by flash chromatography (CH₂Cl₂/MeOH, 95:5→9:1) to give analogue **52** as a colourless oil (8.4 mg, 93 %). TLC (CH₂Cl₂/MeOH, 9:1): *R*_f = 0.38; [α]_D²⁰ = −9.4 (*c* = 0.8, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 0.78 (d, *J* = 6.6 Hz, 3H, 18-CH₃), 0.89–0.96 (m, 6H, 28-H, 16-CH₃), 1.01 (d, *J* = 6.8 Hz, 3H, 10-CH₃), 1.17 (d, *J* = 7.3 Hz, 3H, 24-CH₃), 1.27–1.60 (m, 10H, 19-H, 26-H, 27-H, 20-H, 21-H), 1.82 (br s, 1H, OH), 1.93–2.10 (m, 3H, 18-H, 11-H, 16-H), 2.17–2.42 (m, 5H, 10-H, 14-H, 11-H, 8-H), 2.78–2.89 (m, 1H, 24-H), 3.38–3.47 (m, 1H, 17-H), 3.62–3.75 (m, 3H, 9-H, 8-H, 25-H), 3.79 (s, 3H, OCH₃), 4.71 (t, *J* = 4.6 Hz, 1H, 22-H), 5.23 (dd, *J* = 11.0, 4.2 Hz, 1H, 15-H), 5.38–5.54 (m, 2H, 12-H, 13-H), 6.30 (d, *J* = 2.5 Hz, 1H, 6-H), 6.36 (d, *J* = 2.5 Hz, 1H, 4-H), 6.40 (br s, 1H, NH), 11.6 ppm (br s, 1H, 3-OH); ¹³C NMR (100 MHz, CDCl₃): δ = 9.0 (16-CH₃), 12.0 (24-CH₃), 14.0 (C28), 14.2 (18-CH₃), 15.8 (10-CH₃), 18.9 (C27), 20.8 (C20), 29.4 (C14), 29.7 (C11), 31.6 (C19), 32.0 (C21), 33.3 (C26), 36.3, 36.7, 37.1 (C18), 37.8 (C16), 38.3 (C8), 38.8 (C24), 40.1 (C10), 55.4 (OCH₃), 72.9 (C25), 75.5 (C9), 78.0 (C15), 83.8 (C22), 99.7 (C4), 104.8 (C2), 112.4 (C6), 125.6 (C13), 132.3 (C12), 143.6 (C7), 163.6 (C5), 165.9 (C3), 171.5 (C1), 174.6 (C23); HRMS (ESI): [*M*+Na]⁺ calcd for C₃₃H₅₁NaO₈ 612.35069, found 612.35076.

Biological assays: The biological activity of the compounds was tested by a growth-inhibition assay with fibroblast cells of the mouse cell line L929 (ACC2, DSMZ). The cells were cultivated in Dulbecco's modified Eagle medium with high glucose and 10 % fetal calf serum at 37 °C and 10 % CO₂. Aliquots of 120 μL of suspended cells (50,000 mL^{−1}) were given to 60 μL of serial dilutions of the compounds in 96-well microplates. After five days, the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was measured as a parameter of growth and metabolic activity of the cells and related to control cells that were incubated with the solvent only.

Selected compounds were checked for special phenotypic effects with PtK₂ potoroo cells (ATCC CCL-56). Cells grown on glass coverslips (13 mm diameter) in four-well plates were incubated with the compounds overnight, fixed with cold (−20 °C) acetone-methanol (1:1) for 10 min and labelled for endoplasmic reticulum (ER) with a primary antibody against GRP-94 (1:1000; Affinity BioReagents) and a secondary goat anti-rat IgG antibody conjugated with Alexa Fluor 488 (10 μg mL^{−1}; Molecular Probes).

ATPase assays with submitochondrial particles from beef heart were performed in a final volume of 1000 μL and a pH of 8.0 at room temperature as described previously.^[1] The samples contained 150 μg of bovine protein, 50 mM Tris-HCl (Tris = tris(hydroxymethyl)aminomethane), 50 mM KCl and 2.5 mM MgCl₂. The specific ATPase activity without inhibitor was (0.5 ± 0.13 μmol mg^{−1} min^{−1}).

Acknowledgements

Financial support by the Deutsche Forschungsgemeinschaft (grant Ma 1012/20–1) and the Fonds der Chemischen Industrie is gratefully acknowledged. We also thank Graeme Nicholson (Institute of Organic Chemistry) for measuring the HRMS spectra. In addition, a graduate fellowship for V.V. Vintonyak of the state Baden-Württemberg (LGFG) is acknowledged. We thank Birte Engelhardt and Bettina Hinkelmann for excellent technical assistance.

- [1] B. Kunze, H. Steinmetz, G. Höfle, M. Huss, H. Wiczorek, H. Reichenbach, *J. Antibiot.* **2006**, *59*, 664–668.
- [2] L. Jundt, H. Steinmetz, P. Luger, M. Weber, B. Kunze, H. Reichenbach, G. Höfle, *Eur. J. Org. Chem.* **2006**, 5036–5044.

- [3] B. Kunze, F. Sasse, H. Wiczorek, M. Huss, *FEBS Lett.* **2007**, *581*, 3523–3527.
- [4] For a review about ATP Synthase, see: P. D. Boyer, *J. Biol. Chem.* **2002**, *277*, 39045–39061.
- [5] a) A. R. Salomon, D. W. Voehringer, L. A. Herzenberg, C. Khosla, *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 14766–14771; b) A. R. Salomon, D. W. Voehringer, L. A. Herzenberg, C. Khosla, *Chem. Biol.* **2001**, *8*, 71–80; c) P. A. Wender, O. D. Jankowski, K. Longcore, E. A. Tabet, H. Seto, T. Tomikawa, *Org. Lett.* **2006**, *8*, 589–592; d) P. T. Daniel, U. Koert, J. Schuppan, *Angew. Chem.* **2006**, *118*, 886–908; *Angew. Chem. Int. Ed.* **2006**, *45*, 872–893.
- [6] a) M. D'Ambrosio, A. Guerriero, C. Debitus, F. Pietra, *Helv. Chim. Acta* **1996**, *79*, 51–60; b) M. D'Ambrosio, M. Tato, G. Pocsfalvi, C. Debitus, F. Pietra, *Helv. Chim. Acta* **1999**, *82*, 347–353.
- [7] For recent total syntheses, see: a) Q. Su, L. A. Dakin, J. S. Panek, *J. Org. Chem.* **2007**, *72*, 2–24; b) L. J. Van Orden, B. D. Patterson, S. D. Rychnovsky, *J. Org. Chem.* **2007**, *72*, 5784–5793.
- [8] A. E. Wright, J. C. Botelho, E. Guzmán, D. Harmody, P. Linley, P. J. McCarthy, T. P. Pitts, S. A. Pomponi, J. K. Reed, *J. Nat. Prod.* **2007**, *70*, 412–416.
- [9] A. Zampella, M. V. D'Auria, L. Minale, C. Debitus, C. Roussakis, *J. Am. Chem. Soc.* **1996**, *118*, 11085–11088.
- [10] For a summary, see: V. Wittmann, *Nachr. Chem. Tech. Lab.* **2002**, *50*, 841–845.
- [11] a) R. Jansen, B. Kunze, H. Reichenbach, G. Höfle, *Eur. J. Org. Chem.* **2002**, 917–921; b) B. Kunze, R. Jansen, G. Höfle, H. Reichenbach, *J. Antibiot.* **2004**, *57*, 151–155.
- [12] For reviews, see: a) J. A. Beutler, T. C. McKee, *Curr. Med. Chem.* **2003**, *10*, 787–796; b) L. Yet, *Chem. Rev.* **2003**, *103*, 4283–4306.
- [13] For recent papers covering V-ATPases, see: a) M. Huss, F. Sasse, B. Kunze, R. Jansen, H. Steinmetz, G. Ingenhorst, A. Zeeck, H. Wiczorek, *BMC Biochemistry* **2005**, *6*, 13; b) K. W. Beyenbach, H. Wiczorek, *J. Exp. Biol.* **2006**, *209*, 577–589.
- [14] V. V. Vintonyak, M. E. Maier, *Org. Lett.* **2007**, *9*, 655–658.
- [15] V. V. Vintonyak, M. E. Maier, *Angew. Chem.* **2007**, *119*, 5301–5303; *Angew. Chem. Int. Ed.* **2007**, *46*, 5209–5211.
- [16] For a review, see: A. Fürstner, P. W. Davies, *Chem. Commun.* **2005**, 2307–2320.
- [17] For some illustrative examples, see: a) A. Fürstner, G. Seidel, *Angew. Chem.* **1998**, *110*, 1758–1760; *Angew. Chem. Int. Ed.* **1998**, *37*, 1734–1736; b) A. Fürstner, O. Guth, A. Rumbo, G. Seidel, *J. Am. Chem. Soc.* **1999**, *121*, 11 108–11 113; c) A. Fürstner, C. Mathes, C. W. Lehmann, *Chem. Eur. J.* **2001**, *7*, 5299–5317.
- [18] A. Fürstner, M. Bindl, L. Jean, *Angew. Chem.* **2007**, *119*, 9435–9438; *Angew. Chem. Int. Ed.* **2007**, *46*, 9275–9278.
- [19] The formation of acyliminium ions seems likely in the benzolactone enamides, see: X.-S. Xie, D. Padron, X. Liao, J. Wang, M. G. Roth, J. K. De Brabander, *J. Biol. Chem.* **2004**, *279*, 19755–19763.
- [20] a) D. W. Hart, T. F. Blackburn, J. Schwartz, *J. Am. Chem. Soc.* **1975**, *97*, 679–680; b) S. L. Buchwald, Q. Fang, S. M. King, *Tetrahedron Lett.* **1988**, *29*, 3445–3448.
- [21] L. Jiang, G. E. Job, A. Klapars, S. L. Buchwald, *Org. Lett.* **2003**, *5*, 3667–3669.
- [22] R. Nakamura, K. Tanino, M. Miyashita, *Org. Lett.* **2003**, *5*, 3583–3586.
- [23] R. Shen, J. A. Porco, Jr., *Org. Lett.* **2000**, *2*, 1333–1336.
- [24] A. Fürstner, T. Dierkes, O. Thiel, G. Blanda, *Chem. Eur. J.* **2001**, *7*, 5286–5298.
- [25] K. C. Nicolaou, D. W. Kim, R. Baati, A. O'Brate, P. Giannakakou, *Chem. Eur. J.* **2003**, *9*, 6177–6191.
- [26] Q. Su, J. S. Panek, *J. Am. Chem. Soc.* **2004**, *126*, 2425–2430.
- [27] a) J. A. Marshall, G. M. Schaaf, *J. Org. Chem.* **2001**, *66*, 7825–7831; b) Y. Tamaru, S. Goto, A. Tanaka, M. Shimizu, M. Kimura, *Angew. Chem.* **1996**, *108*, 962–963; *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 878–880.
- [28] a) K. Horita, T. Yoshioka, T. Tanaka, Y. Oikawa, O. Yonemitsu, *Tetrahedron* **1986**, *42*, 3021–3028; b) A. Dahan, M. Portnoy, *J. Org. Chem.* **2001**, *66*, 6480–6482; c) C. Wang, C. J. Forsyth, *Org. Lett.* **2006**, *8*, 2997–3000.

- [29] Z.-Y. Liu, Z.-C. Chen, C.-Z. Yu, R.-F. Wang, R.-Z. Zhang, C.-S. Huang, Z. Yan, D.-R. Cao, J.-B. Sun, G. Li, *Chem. Eur. J.* **2002**, *8*, 3747–3756.
- [30] a) D. R. Hicks, B. Fraser-Reid, *Synthesis* **1974**, 203; b) R. D. Cink, C. J. Forsyth, *J. Org. Chem.* **1995**, *60*, 8122–8123; c) A. B. Smith, III, D.-S. Kim, *J. Org. Chem.* **2006**, *71*, 2547–2557.
- [31] M. Yamaguchi, I. Hirao, *Tetrahedron Lett.* **1983**, *24*, 391–394.
- [32] For a representative procedure, see: Y. Kobayashi, M. Asano, S. Yoshida, A. Takeuchi, *Org. Lett.* **2005**, *7*, 1533–1536.
- [33] J. Suffert, D. Toussaint, *J. Org. Chem.* **1995**, *60*, 3550–3553.
- [34] P. A. Stadler, B. S. Huegi, *Helv. Chim. Acta* **1985**, *68*, 1644–1646.
- [35] For a recent example, see: A. Fürstner, A.-S. Castanet, K. Radkowski, C. W. Lehmann, *J. Org. Chem.* **2003**, *68*, 1521–1528.
- [36] a) J. H. Wengrovius, J. Sancho, R. R. Schrock, *J. Am. Chem. Soc.* **1981**, *103*, 3932–3934; b) R. R. Schrock, D. N. Clark, J. Sancho, J. H. Wengrovius, S. M. Rocklage, S. F. Pedersen, *Organometallics* **1982**, *1*, 1645–1651; c) M. L. Listemann, R. R. Schrock, *Organometallics* **1985**, *4*, 74–83.
- [37] I. Paterson, R. D. M. Davies, A. C. Heimann, R. Marquez, A. Meyer, *Org. Lett.* **2003**, *5*, 4477–4480.
- [38] a) S. Ohira, *Synth. Commun.* **1989**, *19*, 561–564; b) G. J. Roth, B. Liepold, S. G. Müller, H. J. Bestmann, *Synthesis* **2004**, 59–62; c) J. Pietruszka, A. Witt, *Synthesis* **2006**, 4266–4268.
- [39] F. Fülöp, G. Bernáth, P. Sohár, I. Pelczar, *J. Chem. Soc. Perkin Trans. 1* **1984**, 2043–2048.
- [40] M. Panunzio, E. Tamanini, E. Bandini, E. Campana, A. D'Aurizio, P. Vicennati, *Tetrahedron* **2006**, *62*, 12270–12280.
- [41] F. J. P. Feuillet, D. G. Niyadurupola, R. Green, M. Cheeseman, S. D. Bull, *Synlett* **2005**, 1090–1094.
- [42] T. L. Church, C. M. Byrne, E. B. Lobkovsky, G. W. Coates, *J. Am. Chem. Soc.* **2007**, *129*, 8156–8162.
- [43] T. Govender, P. I. Arvidsson, *Tetrahedron Lett.* **2006**, *47*, 1691–1694.
- [44] See the Supporting Information.

Received: October 23, 2007
Published online: February 27, 2008